| 1 |
33280607 | Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms. | 2020 Dec 6 |
1 |
| 2 |
28618970 | Letter regarding Zhao et al. entitled " DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia". | 2017 Jun |
2 |
| 3 |
26794347 | DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. | 2016 May 1 |
1 |
| 4 |
25782327 | DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. | 2015 Sep |
1 |
| 5 |
26372896 | Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. | 2015 Oct 20 |
2 |
| 6 |
23169295 | Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer. | 2012 Dec 4 |
6 |
| 7 |
16292536 | Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. | 2006 Aug |
1 |
| 8 |
17163168 | Pharmacogenomics and colorectal cancer. | 2006 |
1 |
| 9 |
15274386 | 5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients. | 2004 May-Jun |
1 |